Why Most Drugs Fail, and Why Virtual Tissue Models Beat Virtual Cell Models
Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & wellness!
External link. We are not responsible for the content.
Read more ↗More From PsyMed Ventures
Mariëlle van Kooten: Virtual Mitochondrial Models and the Case for Engineering Humans
Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & wellness!
The State of Frontier Neuroscience: This is the century of the brain.
Why now, what’s investable & who wins.
Brain Organoids: from Space to AI with Alysson Muotri
Professor Alysson R. Muotri (geneticist and developmental biologist at UC San Diego) joins for a far out conversation...
Latest News
Ibogaine’s Momentum Is Real. So Is the Safety Gap Nobody’s Solving.
Recent reporting, has documented a string of serious adverse events at overseas psychedelic clinics such as cardiac d...
Was Carlos Castaneda Among the First Psychedelic Grifters?
Author Carlos Castaneda built a fortune on a fabricated Indigenous lineage. A new biography shows how his blueprint s...
University of Miami’s Gift of 1994 Ibogaine IND to HHS Sets a Standard for Open Science
Washington, D.C., August 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS)has welcomed the ...
Who Gets to Heal?
A donor gift with no diagnosis requirement forced a debate inside Thank You Life. Its executive director asks whether...
Weekly Psychedelic Policy Briefing: August 23, 2026
Oregon's psilocybin program posted its first real-world outcome data this week, just as regulators move on fee increa...
What’s stopping psychedelic therapy in China? 5 Questions with medical ethicist Jennifer Docherty
Docherty discusses her interviews about psychedelic end-of-life care with clinicians in Hong Kong.